Results 191 to 200 of about 36,160 (268)

Cost-effectiveness analysis of the 13-valent pneumococcal conjugate vaccine administered to children under 5 years of age in the Republic of Moldova. [PDF]

Med Pharm Rep
Balanuta AM, Bujor D, Paraschiv A, Horodisteanu-Banuh A, Revenco N.   +4 more
europepmc   +1 more source

Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older Adults. [PDF]

Am J Prev Med
Smith KJ, Wateska AR, Nowalk MP, Lin CJ, Harrison LH, Schaffner W, Zimmerman RK.   +6 more
europepmc   +1 more source

III. Characteristics and Differences in Pneumococcal Vaccines; 2. Pneumococcal Conjugate Vaccine

Nihon Naika Gakkai Zasshi, 2015
openaire   +3 more sources

Emergence of non-vaccine Streptococcus pneumoniae serotypes colonizing the nasopharynx of children under five years of age in the 13-valent pneumococcal conjugate vaccine era in Tanzania. A short communication. [PDF]

Vaccine
Ngocho JS, van der Gaast-de Jongh CE, Sebba J, Mtei M, Kinabo G, Mmbaga BT, de Jonge MI.   +6 more
europepmc   +1 more source

Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit. [PDF]

Infect Dis Ther
Perdrizet J, Ta A, Huang L, Wannaadisai W, Ilic A, Hayford K, Sabra A.   +6 more
europepmc   +1 more source

Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults. [PDF]

Infect Dis Ther
Rey-Ares L, Averin A, Mac Mullen M, Hariharan D, Atwood M, Carballo C, Huang L.   +6 more
europepmc   +1 more source

Effect of 10-valent pneumococcal conjugate vaccine on trends of pneumococcal meningitis in children under five years, Uganda, 2003-2022. [PDF]

BMC Infect Dis
Nuwamanya Y, Ampeire I, Baganizi M, Atugonza R, Nsubuga F, Kwesiga B, Migisha R, Bulage L, Kadobera D, Ario AR, Kisakye A.   +10 more
europepmc   +1 more source